Clinical Trial Update: Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients [Phase 4]

View source ↗

Summary

Phase 4 study evaluation of [18F]Florbetapir PET feasibility for assessing multiple sclerosis; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Florbetapir (Florbetapir)

Snippet

Sponsor: Institute for Neurodegenerative Disorders | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2021-08-27